Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis

C. L. M. Sudlow; Carl Edward Counsell

doi:10.1136/bmj.326.7385.388

Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis

C. L. M. Sudlow, Carl Edward Counsell

Research output: Contribution to journal › Article › peer-review

68 Citations (Scopus)

Abstract

The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.

Original language	English
Pages (from-to)	388-392
Number of pages	4
Journal	British Medical Journal
Volume	326
DOIs	https://doi.org/10.1136/bmj.326.7385.388
Publication status	Published - 2003

Keywords

RANDOMIZED CONTROLLED-TRIAL
SECONDARY PROGRESSIVE MS
PLACEBO-CONTROLLED TRIAL
DOUBLE-BLIND
INTERFERON BETA-1B
GLATIRAMER ACETATE
NATURAL-HISTORY
CLINICAL-TRIALS
FINAL REPORT
RELAPSE RATE

Access to Document

10.1136/bmj.326.7385.388

Cite this

@article{28df8f12d5cf4d31b687d27cfeb97a18,

title = "Problems with UK government{\textquoteright}s risk sharing scheme for assessing drugs for multiple sclerosis",

abstract = "The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.",

keywords = "RANDOMIZED CONTROLLED-TRIAL, SECONDARY PROGRESSIVE MS, PLACEBO-CONTROLLED TRIAL, DOUBLE-BLIND, INTERFERON BETA-1B, GLATIRAMER ACETATE, NATURAL-HISTORY, CLINICAL-TRIALS, FINAL REPORT, RELAPSE RATE",

author = "Sudlow, {C. L. M.} and Counsell, {Carl Edward}",

year = "2003",

doi = "10.1136/bmj.326.7385.388",

language = "English",

volume = "326",

pages = "388--392",

journal = "BMJ",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis

AU - Sudlow, C. L. M.

AU - Counsell, Carl Edward

PY - 2003

Y1 - 2003

N2 - The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.

AB - The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.

KW - RANDOMIZED CONTROLLED-TRIAL

KW - SECONDARY PROGRESSIVE MS

KW - PLACEBO-CONTROLLED TRIAL

KW - DOUBLE-BLIND

KW - INTERFERON BETA-1B

KW - GLATIRAMER ACETATE

KW - NATURAL-HISTORY

KW - CLINICAL-TRIALS

KW - FINAL REPORT

KW - RELAPSE RATE

U2 - 10.1136/bmj.326.7385.388

DO - 10.1136/bmj.326.7385.388

M3 - Article

VL - 326

SP - 388

EP - 392

JO - BMJ

JF - BMJ

SN - 0959-8146

ER -

Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this